Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 12/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926772 | 0.93 | CA1 (0.55) | CA2CA1CTSKCTSS | |
| SCHEMBL27343844 | 0.92 | CA2 (0.48) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL7804092 | 0.92 | CA2 (0.48) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL17377641 | 0.92 | ZDHHC7 (0.46) | CA2CA1 | |
| SCHEMBL8490442 | 0.92 | ZDHHC7 (0.46) | CA2CA1 | |
| SCHEMBL28311243 | 0.91 | ALDH1A1 (0.42) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL27817034 | 0.91 | CA2 (0.41) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL27395164 | 0.91 | CA2 (0.41) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL29021012 | 0.89 | CA2 (0.42) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL3325978 | 0.87 | CTSK (0.39) | CA2CA1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150316849-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING ESTER GROUP | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | APOSENSE LTD. (IL) | 2011-10-20 | — | — | US | disclosed |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | APOSENSE LTD. (IL) | 2011-10-20 | — | — | US | disclosed |
| US-7947253-B2 | compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets | APOSENSE LTD. (IL) | 2011-05-24 | — | — | US | disclosed |
| US-7947253-B2 | compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets | APOSENSE LTD. (IL) | 2011-05-24 | — | — | US | disclosed |
| US-7670590-B2 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-7670590-B2 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | NST NEUOROSURIVAL TECHNOLOGIES LTD. (IL) | 2008-11-13 | — | — | US | disclosed |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | NST NEUOROSURIVAL TECHNOLOGIES LTD. (IL) | 2008-11-13 | — | — | US | disclosed |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2008-01-17 | — | — | US | disclosed |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2008-01-17 | — | — | US | disclosed |
| US-7270799-B2 | Perturbed membrane-binding compounds and methods of using the same | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2007-09-18 | — | — | US | disclosed |
| US-7270799-B2 | Perturbed membrane-binding compounds and methods of using the same | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2007-09-18 | — | — | US | disclosed |
| EP-1130469-A1 | A radiation-sensitive resist material and a process for device fabrication using the same | LUCENT TECHNOLOGIES INC. (US) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | ANXA5, SELPLG, ANXA6 | CA2 1675/4885CA1 2966/4885CTSK 1802/4885 |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | ANXA5, SELPLG, ANXA6 | CA2 1722/4885CA1 3098/4885CTSK 1783/4885 |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | ANXA5, SELPLG, ANXA6 | CA2 1722/4885CA1 3098/4885CTSK 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.